• FirefoxInstall the new Firefox »
  •  Dow Up0.86% Nasdaq Up0.90%

    Chimerix, Inc. (CMRX)

    -NasdaqGM
    40.48 0.00(0.00%) 4:00PM EST
    |After Hours : 40.48 0.00 (0.00%) 5:07PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Chimerix, Inc.
    2505 Meridian Parkway
    Suite 340
    Durham, NC 27713
    United States - Map
    Phone: 919-806-1074
    Fax: 919-806-1146
    Website: http://www.chimerix.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:67

    Business Summary 

    Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Chimerix, Inc.

    Corporate Governance 
    Chimerix, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. M. Michelle Berrey M.D., MPH., 48
    Chief Exec. Officer, Pres, Chief Medical Officer and Director
    439.00K0.00
    Mr. Michael D. Rogers Ph.D., 61
    Chief Devel. Officer
    297.00K0.00
    Mr. Timothy W. Trost CPA, 57
    Chief Financial Officer, Sr. VP and Corp. Sec.
    N/AN/A
    Mr. Joseph T. Schepers , 57
    Exec. Director of Investor Relations and Corp. Communications
    N/AN/A
    Dr. Michael A. Alrutz J.D., Ph.D., 45
    VP and Gen. Counsel
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.